title: Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome.
abstract: The capillary leak syndrome, responsible for fluid loss into the interstitial space, represents one of the major cardiovascular toxicities of IL-2 during the immunotherapy of cancer. The mechanisms involved in the increased vascular permeability have still to be better understood. The present study was carried out to investigate the role of the complement system in mediating the IL-2 vascular toxicity. The study was performed in metastatic renal cancer patients, treated with IL-2 through a 24-hour i.v. infusion at a daily dose of 3 x 10(6) U/m2 for 5 consecutive days, corresponding to one IL-2 course. Six IL-2 courses were evaluated. C3 and C4 were measured daily during IL-2 infusion, and 2 and 5 days after its interruption. IL-2 administration induced a significant decrease in both C3 and C4 mean levels, which became within the normal range 5 days after the end of IL-2 infusion. These results show that IL-2 administration may directly activate the complement system through the classical pathway, which might play a role in determining the increased vascular permeability.
authors.affiliation: Division of Oncological Radiotherapy, San Gerardo Hospital, Monza, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Lissoni
authors.forename: S
authors.initials: S
authors.lastname: Barni
authors.forename: G
authors.initials: G
authors.lastname: Cattaneo
authors.forename: C
authors.initials: C
authors.lastname: Archili
authors.forename: S
authors.initials: S
authors.lastname: Crispino
authors.forename: G
authors.initials: G
authors.lastname: Tancini
authors.forename: L
authors.initials: L
authors.lastname: D'Angelo
authors.forename: S
authors.initials: S
authors.lastname: Magni
authors.forename: G
authors.initials: G
authors.lastname: Fiorelli
mesh_terms: D002199:Capillary Permeability / Q000187:drug effects*; D003167:Complement Activation; D003176:Complement C3 / Q000378:metabolism; D003181:Complement C4 / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy; D013577:Syndrome
chemical_list: D003176:Complement C3; D003181:Complement C4; D007376:Interleukin-2